‘Velcade Inj,’ soon to be expired in patent, attracts interests of 3 companies, such as Chong Kun Dang
Expiring on the 28th, the patent of ‘Velcade Inj(generic name: bortezomib),’ a Janssen Korea’s multiple myeloma treatment, has attracted attention of domestic pharmaceutical companies.
According to the Ministry of Food and Drug Safety, Chong Kun Dang, Boryung Pharm and Samyang Biopharmaceuticals...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
